JP5110767B2 - グルカンベースのワクチン - Google Patents

グルカンベースのワクチン Download PDF

Info

Publication number
JP5110767B2
JP5110767B2 JP2004505087A JP2004505087A JP5110767B2 JP 5110767 B2 JP5110767 B2 JP 5110767B2 JP 2004505087 A JP2004505087 A JP 2004505087A JP 2004505087 A JP2004505087 A JP 2004505087A JP 5110767 B2 JP5110767 B2 JP 5110767B2
Authority
JP
Japan
Prior art keywords
glucan
antibodies
cells
antibody
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004505087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535298A (ja
JP2005535298A5 (enExample
Inventor
ルシアーノ ポロネリ，
アントニオ カッソネ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2005535298A publication Critical patent/JP2005535298A/ja
Publication of JP2005535298A5 publication Critical patent/JP2005535298A5/ja
Application granted granted Critical
Publication of JP5110767B2 publication Critical patent/JP5110767B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2004505087A 2002-05-15 2003-05-15 グルカンベースのワクチン Expired - Fee Related JP5110767B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0211118.5 2002-05-15
GBGB0211118.5A GB0211118D0 (en) 2002-05-15 2002-05-15 Vaccines
PCT/IB2003/002460 WO2003097091A2 (en) 2002-05-15 2003-05-15 Glucan-based vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009294467A Division JP2010131017A (ja) 2002-05-15 2009-12-25 グルカンベースのワクチン

Publications (3)

Publication Number Publication Date
JP2005535298A JP2005535298A (ja) 2005-11-24
JP2005535298A5 JP2005535298A5 (enExample) 2012-07-26
JP5110767B2 true JP5110767B2 (ja) 2012-12-26

Family

ID=9936711

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004505087A Expired - Fee Related JP5110767B2 (ja) 2002-05-15 2003-05-15 グルカンベースのワクチン
JP2009294467A Pending JP2010131017A (ja) 2002-05-15 2009-12-25 グルカンベースのワクチン
JP2012166700A Expired - Fee Related JP5684758B2 (ja) 2002-05-15 2012-07-27 グルカンベースのワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009294467A Pending JP2010131017A (ja) 2002-05-15 2009-12-25 グルカンベースのワクチン
JP2012166700A Expired - Fee Related JP5684758B2 (ja) 2002-05-15 2012-07-27 グルカンベースのワクチン

Country Status (14)

Country Link
US (4) US20050208079A1 (enExample)
EP (2) EP1506009B1 (enExample)
JP (3) JP5110767B2 (enExample)
AT (2) ATE395080T1 (enExample)
AU (1) AU2003241104A1 (enExample)
CA (2) CA2830619A1 (enExample)
CY (1) CY1108234T1 (enExample)
DE (2) DE60320979D1 (enExample)
DK (1) DK1506009T3 (enExample)
ES (1) ES2306871T3 (enExample)
GB (1) GB0211118D0 (enExample)
PT (1) PT1506009E (enExample)
SI (1) SI1506009T1 (enExample)
WO (1) WO2003097091A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8422084B2 (en) 2006-12-22 2013-04-16 Fuji Xerox Co., Ltd. Image processing apparatus, image reading apparatus, image forming apparatus with units to calculate spectral reflectance and relating coefficient and methods therefor

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
JP2007531536A (ja) * 2004-04-05 2007-11-08 ユニヴェルシテ ボルドー ２ Ｃｄ２３に結合するペプチドおよびペプチド模倣体
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
JP2008543907A (ja) * 2005-06-27 2008-12-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2007084661A2 (en) * 2006-01-17 2007-07-26 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
US20070253985A1 (en) * 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
AU2009243094B2 (en) 2006-11-06 2015-02-12 Massachusetts Institute Of Technology Immunomodulating compositions and methods of use thereof
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
AU2013203785B2 (en) * 2006-11-06 2016-11-17 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
JP6082174B2 (ja) * 2006-11-06 2017-02-15 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ 免疫調節組成物及びその使用方法
ES2495744T5 (es) * 2007-11-26 2018-04-26 Glaxosmithkline Biologicals S.A. Glucanos con adyuvante
ES2599908T3 (es) 2007-11-26 2017-02-06 Glaxosmithkline Biologicals Sa Glucanos beta-1,3-enlazados conjugados
CA2737455A1 (en) 2008-09-18 2010-03-25 Novartis Ag Vaccine adjuvant combinations
NL1036661C2 (en) 2009-03-04 2010-09-07 Serrix B V Anti-fungal compounds & compositions.
EP2405923A1 (en) * 2009-03-10 2012-01-18 Palmed Teva Ltd Novel coprinus comatus and tremella mesenterica mushroom strains, products and extracts thereof and compositions comprising them
EP2470205A1 (en) 2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation
BR112012004806B8 (pt) 2009-09-02 2022-10-04 Novartis Ag composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
UA103283C2 (ru) * 2010-05-14 2013-09-25 Олтек, Инк. Способ выявления компонентов клеточной стенки дрожжей
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
EP2652511B8 (en) 2010-12-14 2017-06-28 GlaxoSmithKline Biologicals SA Flow cytometry analysis of materials adsorbed to metal salts
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
JP6088507B2 (ja) 2011-07-08 2017-03-01 ノバルティス アーゲー チロシンライゲーションの方法
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
HUE030175T2 (en) 2012-03-07 2017-04-28 Glaxosmithkline Biologicals Sa Arginine salt of TLR7 agonist
CN104159602B (zh) 2012-03-08 2017-10-24 葛兰素史密丝克莱恩生物有限公司 加强疫苗的含佐剂制剂
CN104812243B (zh) * 2012-04-30 2018-06-05 生物治疗公司 用于β-葡聚糖免疫疗法的组合物和方法
EP2950819B1 (en) 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Intradermal delivery of immunological compositions comprising toll-like receptor agonists
CN103083663B (zh) * 2013-02-04 2014-12-10 江苏省农业科学院 一种免疫增强剂、灭活疫苗及其制备方法
PL2968427T3 (pl) * 2013-03-12 2023-02-27 Wellstat Vaccines, Llc Koniugat do indukowania przeciwciał ukierunkowanych na polisacharydy ściany komórkowej grzybów
MX2016000393A (es) 2013-07-11 2016-10-26 Novartis Ag Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana.
AU2014357446B2 (en) * 2013-12-05 2020-05-07 Biothera, Inc. Beta-glucan assay methods
PL3071235T3 (pl) * 2015-01-26 2018-05-30 Kaleido Biosciences Inc Glikanowe środki terapeutyczne i związane z nimi sposoby
CN104771498A (zh) * 2015-03-13 2015-07-15 臧海阳 一种治疗热毒蕴结型痄腮的中药组合物
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
WO2019141774A1 (en) 2018-01-19 2019-07-25 Miltenyi Biotec Gmbh Regulatory t cell expressing a chimeric antigen receptor
US11701417B2 (en) * 2019-03-27 2023-07-18 West Virginia University Vaccine formulation to protect against pertussis
WO2023002252A1 (en) 2021-07-21 2023-01-26 Bioatlantis Limited Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same
US20250186596A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466289B (sv) * 1984-09-19 1992-01-27 James Hoffman Makrofagstimulerande komposition jaemte foerfarande foer dess framstaellning
JPS6383012A (ja) * 1986-09-26 1988-04-13 Nonogawa Shoji:Kk 化粧料
AU650626B2 (en) * 1989-09-08 1994-06-30 Alpha-Beta Technology, Inc. Method for producing soluble glucans
EP0471954A3 (en) 1990-08-13 1993-03-03 American Cyanamid Company Immunogenic conjugates of nontoxic oligosaccharide derived from bordetella pertussis lipooligosaccharide
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
EP0616034B1 (en) * 1993-03-05 2004-10-20 Wyeth Holdings Corporation Plasmid for production of CRM protein and diphtheria toxin
CN1094288A (zh) * 1993-04-23 1994-11-02 福建省微生物研究所 利用红色诺卡氏菌制造细胞壁骨架粉末的方法
NO300692B1 (no) 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US6309642B1 (en) * 1997-04-28 2001-10-30 The Research And Development Institute, Inc. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
JPH09309842A (ja) * 1996-05-20 1997-12-02 Kureha Chem Ind Co Ltd 新規な生理活性物質、その製造方法及び医薬組成物
AU760669B2 (en) * 1998-04-28 2003-05-22 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
JP4230635B2 (ja) 2000-02-29 2009-02-25 富士フイルム株式会社 デジタルカメラ

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8422084B2 (en) 2006-12-22 2013-04-16 Fuji Xerox Co., Ltd. Image processing apparatus, image reading apparatus, image forming apparatus with units to calculate spectral reflectance and relating coefficient and methods therefor

Also Published As

Publication number Publication date
US20050208079A1 (en) 2005-09-22
US8679506B2 (en) 2014-03-25
EP1506009B1 (en) 2008-05-14
US20110059120A1 (en) 2011-03-10
DE60336027D1 (de) 2011-03-24
ATE395080T1 (de) 2008-05-15
WO2003097091A2 (en) 2003-11-27
US8398990B2 (en) 2013-03-19
US20070141088A1 (en) 2007-06-21
CY1108234T1 (el) 2014-02-12
JP2005535298A (ja) 2005-11-24
CA2830619A1 (en) 2003-11-27
JP2012224636A (ja) 2012-11-15
US20130171187A1 (en) 2013-07-04
JP5684758B2 (ja) 2015-03-18
HK1114335A1 (en) 2008-10-31
SI1506009T1 (sl) 2008-10-31
JP2010131017A (ja) 2010-06-17
EP1891970A1 (en) 2008-02-27
ES2306871T3 (es) 2008-11-16
WO2003097091A3 (en) 2004-03-04
EP1506009A2 (en) 2005-02-16
CA2485847A1 (en) 2003-11-27
CA2485847C (en) 2013-12-31
DK1506009T3 (da) 2008-09-01
GB0211118D0 (en) 2002-06-26
ATE497781T1 (de) 2011-02-15
HK1069125A1 (en) 2005-05-13
DE60320979D1 (de) 2008-06-26
AU2003241104A1 (en) 2003-12-02
US7824688B2 (en) 2010-11-02
EP1891970B1 (en) 2011-02-09
PT1506009E (pt) 2008-08-14

Similar Documents

Publication Publication Date Title
JP5110767B2 (ja) グルカンベースのワクチン
JP4827196B2 (ja) 髄膜炎菌類タンパク質ｎｍｂ１８７０のドメインおよびエピトープ
EP0549617B1 (en) Improved vaccine compositions
CA1340958C (en) Synthetic peptides representing a t-cell epitope as a carrier molecule for conjugate vaccines
JP7074793B2 (ja) 髄膜炎菌ワクチン
JP2010202672A (ja) 細菌性髄膜炎に関する粘膜組合せワクチン
JP2017523985A (ja) 抗原用担体分子
WO2023202607A1 (zh) 多价肺炎球菌多糖结合疫苗的成分及其应用
CN107961369B (zh) 多价脑膜炎球菌缀合疫苗及其制备方法
JP2018522978A (ja) 免疫原性組成物
US20030068324A1 (en) Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid
HK1069125B (en) Beta-glucan-based anti-fungal vaccines
HK1114335B (en) Beta glucan-based vaccines free of mannoprotein
JP2013510188A (ja) 黄色ブドウ球菌に由来する菌血症関連抗原
CN110652585A (zh) 多糖-蛋白缀合物免疫制剂及其制备与应用
Hung The role of novel Neisseria meningitidis antigens in the pathogenesis of infection and their potential as vaccine candidates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060515

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20060515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060703

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20060703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090924

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120529

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120711

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120912

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121009

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151019

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees